[Cathecholamine].
Toya
Yoshiyuki
Y
Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine.
Ebina
Toshiaki
T
Umemura
Satoshi
S
D000818:Animals; D001342:Autonomic Nervous System Diseases / Q000209:etiology / Q000628:therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002395:Catecholamines / Q000378:metabolism* / Q000502:physiology; D005136:Eye Proteins / Q000502:physiology; D005440:Fluid Therapy; D051606:G-Protein-Coupled Receptor Kinase 1; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000628:therapy; D007022:Hypotension / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D011494:Protein Kinases / Q000502:physiology; D011724:Pyridazines / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000378:metabolism / Q000502:physiology; D006435:Renal Dialysis / Q000009:adverse effects; D013566:Sympathomimetics / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D002395:Catecholamines; D005136:Eye Proteins; D011724:Pyridazines; D011941:Receptors, Adrenergic; D013566:Sympathomimetics; D011494:Protein Kinases; D051606:G-Protein-Coupled Receptor Kinase 1; C496764:GRK1 protein, human; C027784:amezinium